PDP1 and infection: The recent development of synthetic PDH inhibitors with selectivity demonstrated through molecular docking, mutagenesis, enzymatic assays, and inhibition kinetic analysis [14–17] suggests that it will be possible to therapeutically-manipulate bacterial carbon flux during infection.